Cavitation Technologies, Inc. - Quarter Report: 2013 March (Form 10-Q)

March 31, 2013 DOC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2013
Commission File Number: 0-29901

Cavitation Technologies, Inc.
(Exact name of Registrant as Specified in its Charter)

Nevada	20-4907818
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA 91311
(Address, including Zip Code, of Principal Executive Offices )

(818) 718-0905
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.
YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨
(Do not check if a smaller reporting company)

Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ¨ NO x

As of May 15, 2013, the issuer had 156,899,702 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
Part I.	FINANCIAL INFORMATION	2

Item 1.	Consolidated Financial Statements	2

	Consolidated Balance Sheets at March 31, 2013 (unaudited) and June 30, 2012	2

	Consolidated Statements of Operations - Three and Nine Months Ended March 31, 2013 (unaudited) and March 31, 2012 (unaudited), and the period from January 29, 2007 (Inception) through March 31, 2013 (unaudited)	3

	Consolidated Statement of Stockholders' Deficit - January 29, 2007 (Inception) through March 31, 2013 (unaudited)	4

	Consolidated Statements of Cash Flows - Nine Months Ended March 31, 2013 (unaudited) and March 31, 2012 (unaudited), and the period from January 29, 2007 (Inception) through March 31, 2013 (unaudited)	8

	Notes to Consolidated Financial Statements (unaudited)	9

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

Part II.	OTHER INFORMATION	21

Item 1.	Legal Proceedings	21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

Signatures		24

PART I - FINANCIAL INFORMATION

ITEM 1 - Consolidated Financial Statements
CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS

		March 31,		June 30,
		2013		2012
		(Unaudited)
ASSETS

Current assets:
Cash and cash equivalents	$	301,006	$	137,249
Inventory		154,209		141,057
Related party advances		46,525		23,853
Total current assets		501,740		302,159

Property and equipment, net		143,455		135,615
Patents, net		147,547		123,158
Other assets		9,500		9,500
Total assets	$	802,242	$	570,432

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:
Accounts payable	$	165,263	$	187,095
Accrued expenses		81,102		126,767
Accrued payroll		1,261,975		992,806
Deferred revenue		36,533		283,977
Convertible notes payable, net of discounts		-		29,083
Derivative liability		-		6,271
Related party payables		1,147		59,608
Short term loans - related party		185,000		100,000
Short-term loans		34,521		274,521
Advances from partner		840,663		125,000
Bank loan		-		349,276
Total current liabilities		2,606,204		2,534,404

Long-term Liabilities:
Convertible note payable, net of discount		23,630		-


Commitments and contingencies, Note 11

Stockholders' deficit:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2013 and June 30, 2012.		-		-
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 156,899,702, shares and 164,469,569 shares are issued and outstanding as of March 31, 2013 and June 30, 2012, respectively		156,901		165,971
Additional paid-in capital		16,836,280		16,650,959
Deficit accumulated during the development stage		(18,820,773)		(18,780,902)
Total stockholders' deficit		(1,827,592)		(1,963,972)
Total liabilities and stockholders' deficit	$	802,242	$	570,432

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS

										January 29, 2007,
										Inception,
		For the Three Months Ended				For the Nine Months Ended				Through
		March 31,				March 31,				March 31,
		2013		2012		2013		2012		2013
		(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Revenue	$	529,327	$	51,818	$	1,223,115	$	165,972	$	2,000,257
Cost of revenue		16,726		12,260		21,665		35,274		153,373
Gross profit		512,601		39,558		1,201,450		130,698		1,846,884
General and administrative expenses		296,647		502,820		1,063,089		1,203,887		14,075,686
Research and development expenses		18,341		64,735		84,194		126,940		5,524,590
Total operating expenses		314,988		567,555		1,147,283		1,330,827		19,600,276
Profit (Loss) from operations		197,613		(527,997)		54,167		(1,200,129)		(17,753,392)
Interest expense and other		(26,948)		(25,337)		(94,038)		(155,138)		(884,270)
Profit (Loss) before Income Taxes		170,665		(553,334)		(39,871)		(1,355,267)		(18,637,662)
Income Tax Expense		-		-		-		-		-
Net Profit (Loss)		170,665		(553,334)		(39,871)		(1,355,267)		(18,637,662)
Deemed dividends to preferred stockholders		-		(1,286)		-		(4,286)		(183,111)
Net Profit (Loss) available to common stockholders	$	170,665	$	(554,620)	$	(39,871)	$	(1,359,553)	$	(18,820,773)

Net Profit (Loss) available to common shareholders per share:
Basic and Diluted	$	0.00	$	(0.00)	$	(0.00)	$	(0.01)

Weighted average shares outstanding:
Basic and Diluted		156,899,702		160,767,919		161,342,944		158,090,480

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)

										Deficit
										Accumulated
										During the
	Series A Preferred			Common Stock				Additional Paid-in		Development
	Shares		Amount	Shares		Amount		Capital		Stage		Total

Balance at inception, January 29, 2007	-	$	-	-	$	-	$	-	$	-	$	-

Common stock issued as payment for services on January 29, 2007				42,993,630		42,994		(21,994)				21,000
Common stock issued as payment for services on March 31, 2008				6,428,904		6,429		1,123,971				1,130,400
Common stock issued as payment for services on April 16, 2008				51,180		51		8,949				9,000
Common stock issued as payment for services on April 22, 2008				102,360		102		17,898				18,000
Common stock issued as payment for services on June 18, 2008				3,787,320		3,788		662,212				666,000
Common stock sold for cash on June 30, 2008				2,047,200		2,047		497,953				500,000
Amortization of discount on convertible preferred stock								47,879		(47,879)		-
Net loss										(2,681,782)		(2,681,782)

Balance at June 30, 2008	-		-	55,410,594		55,411		2,336,868		(2,729,661)		(337,382)

Common stock sold in connection with reverse merger for cash on October 3, 2008				2,149,560		2,150		122,850				125,000
Preferred stock sold for cash on March 17, 2009	111,111		111					99,889				100,000
Preferred stock - beneficial conversion feature								11,111		(11,111)		-
Common stock sold for cash on April 22, 2009				499,998		500		99,500				100,000
Common stock sold for cash on June 4, 2009				499,998		500		99,500				100,000
Common stock sold for cash on June 22, 2009				300,000		300		49,700				50,000
Common stock sold for cash on June 30, 2009				300,000		300		49,700				50,000
Bio common stock outstanding before reverse merger on October 3, 2008				27,840,534		27,840		(27,840)				-
Common stock issued as payment for services on September 22, 2008				150,000		150		17,850				18,000
Common stock issued as payment for services on December 3, 2008				450,000		450		187,150				187,600
Common stock issued as payment for services on December 17, 2008				300,000		300		131,800				132,100
Common stock issued as payment for services on February 27, 2009				590,565		591		156,893				157,484
Common stock issued as payment for services on March 11, 2009				86,550		86		26,853				26,939
Common stock issued as payment for services on March 22, 2009				150,000		150		50,350				50,500
Common stock issued as payment for services on April 23, 2009				29,415		29		9,285				9,314
Common stock issued as payment for services on May 28, 2009				152,379		152		38,959				39,111
Common stock issued as payment for services on June 4, 2009				37,500		38		9,837				9,875
Common stock issued as payment for services on June 30, 2009				37,500		38		8,712				8,750
Warrants issued with convertible debt in December 2008, January 2009 and February 2009								49,245				49,245
Amortization of discount on convertible preferred stock								107,835		(107,835)		-
Warrants issued as payment for services on May 27, 2009								56,146				56,146
Warrants issued as payment for services on June 3, 2009								84,219				84,219
Warrants issued as payment for services on June 30, 2009								5,678				5,678
Issuance of stock options as payment for services on August 8, 2008								229,493				229,493
Issuance of stock options as payment for services on October 1, 2008								4,598				4,598
Issuance of stock options as payment for services on October 7, 2008								22,770				22,770
Issuance of stock options as payment for services on October 21, 2008								47				47
Issuance of stock options as payment for services on October 28, 2008								33				33
Issuance of stock options as payment for services on January 19, 2009								50,571				50,571
Net loss										(2,495,991)		(2,495,991)

Balance at June 30, 2009	111,111	$	111	88,984,593	$	88,985	$	4,089,602	$	(5,344,598)	$	(1,165,900)

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) (Continued)

										Deficit
										Accumulated
										During the
	Series A Preferred			Common Stock				Additional Paid-in		Development
	Shares		Amount	Shares		Amount		Capital		Stage		Total

Balance at June 30, 2009	111,111	$	111	88,984,593	$	88,985	$	4,089,602	$	(5,344,598)	$	(1,165,900)

Common stock issued as payment for services on July 27, 2009				17,358,000		17,358		3,886,279				3,903,637
Common stock issued as payment for services on August 5, 2009				165,000		165		44,935				45,100
Common stock issued as payment for services on September 16, 2009				190,011		190		42,209				42,399
Common stock issued as payment for services on October 7, 2009				130,500		131		42,500				42,631
Common stock issued as payment for services on October 16, 2009				100,911		101		34,209				34,310
Common stock issued as payment for services on October 23, 2009				30,000		30		9,270				9,300
Common stock issued as payment for services on October 29, 2009				37,500		38		13,463				13,501
Common stock issued as payment for services on November 3, 2009				37,500		37		13,464				13,501
Common stock issued as payment for services on November 10, 2009				35,102		35		12,251				12,286
Common stock issued as payment for services on November 16, 2009				1,505,000		1,505		405,944				407,449
Common stock issued as payment for services on November 30, 2009				60,000		60		17,340				17,400
Common stock issued as payment for services on December 4, 2009				49,157		49		12,240				12,289
Common stock issued as payment for services on January 11, 2010				121,286		121		30,200				30,321
Common stock issued as payment for services on February 1, 2010				5,125,102		5,125		1,071,146				1,076,271
Common stock issued as payment for services on February 11, 2010				500,000		500		109,500				110,000
Common stock issued as payment for services on February 15, 2010				127,500		128		26,648				26,776
Common stock issued as payment for services on February 23, 2010				135,000		135		26,865				27,000
Common stock issued as payment for services on March 5, 2010				346,098		346		82,897				83,243
Common stock issued as payment for services on March 12, 2010				70,000		70		13,455				13,525
Common stock issued as payment for services on March 22, 2010				50,000		50		8,450				8,500
Common stock issued as payment for services on April 12, 2010				127,282		127		16,420				16,547
Common stock issued as payment for services on April 19, 2010				100,000		100		16,900				17,000
Common stock issued as payment for services on April 29, 2010				1,700,000		1,700		253,300				255,000
Common stock issued as payment for services on May 10, 2010				773,750		774		115,288				116,062
Common stock issued as payment for services on May 24, 2010				219,092		219		43,599				43,818
Common stock issued as payment for services on June 1, 2010				163,794		164		29,319				29,483
Common stock issued as payment for services on June 9, 2010				333,333		333		59,667				60,000
Common stock issued as payment for services on June 14, 2010				46,544		47		8,331				8,378
Common stock issued for debt and accrued interest conversion on August 7, 2009				1,122,375		1,122		189,681				190,803
Conversion feature on convertible notes payable								63,601				63,601
Common stock sold for cash on October 13, 2009				208,104		208		34,156				34,364
Common stock sold for cash on October 16, 2009				2,980,734		2,981		493,808				496,789
Common stock sold for cash on November 4, 2009				217,117		217		36,183				36,400
Common stock sold for cash on November 17, 2009				421,529		422		71,748				72,170
Common stock sold for cash on December 4, 2009				352,451		352		59,565				59,917
Common stock sold for cash on January 6, 2010				58,058		58		9,812				9,870
Common stock sold for cash on February 4, 2010				888,235		888		150,112				151,000
Common stock sold for cash on March 2, 2010				743,746		744		125,693				126,437
Common stock sold for cash on March 12, 2010				352,941		353		59,647				60,000
Common stock sold for cash on April 19, 2010				125,000		125		14,875				15,000
Common stock sold for cash on June 1, 2010				700,000		700		69,300				70,000
Common stock issued for conversion of note payable on June 1, 2010				2,789,217		2,789		276,133				278,922
Common stock sold for cash on June 24, 2010				1,000,000		1,000		99,000				100,000
Warrants issued as payment for services on July 15, 2009								13,205				13,205
Warrants issued as payment for services on February 11, 2010								131,376				131,376
Conversion feature of note payable on June 1, 2010								223,137				223,137
Dividends on preferred stock										(6,000)		(6,000)
Net loss										(8,196,462)		(8,196,462)

Balance at June 30, 2010	111,111	$	111	130,581,562	$	130,582	$	12,656,723	$	(13,547,060)	$	(759,644)

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) (Continued)

										Deficit
										Accumulated
										During the
	Series A Preferred			Common Stock				Additional Paid-in		Development
	Shares		Amount	Shares		Amount		Capital		Stage		Total

Balance at June 30, 2010	111,111	$	111	130,581,562	$	130,582	$	12,656,723	$	(13,547,060)	$	(759,644)

Common stock issued as payment for services on July 8, 2010				349,571		350		52,086				52,436
Common stock issued as payment for services on August 3, 2010				1,854,009		1,854		350,406				352,260
Common stock issued as payment for services on August 30, 2010				75,000		75		11,175				11,250
Common stock issued as payment for services on September 8, 2010				237,192		237		35,342				35,579
Common stock issued as payment for services on October 1, 2010				473,517		474		70,554				71,028
Common stock issued as payment for services on November 1, 2010				1,020,482		1,020		131,643				132,663
Common stock issued as payment for services on November 22, 2010				100,000		100		11,900				12,000
Common stock issued as payment for services on December 7, 2010				459,056		459		50,037				50,496
Common stock issued as payment for services on January 10, 2011				116,916		117		13,913				14,030
Common stock issued as payment for services on February 14, 2011				1,264,883		1,265		137,872				139,137
Common stock issued as payment for services on March 10, 2011				219,767		220		21,757				21,977
Common stock issued as payment for services on March 22, 2011				510,000		510		50,490				51,000
Common stock issued as payment for services on April 1, 2011				816,145		816		80,799				81,615
Common stock issued as payment for services on May 17, 2011				276,203		276		27,343				27,619
Common stock issued as payment for services on June 13, 2011				333,924		334		33,058				33,392
Common stock issued as payment for services on June 14, 2011				8,096,990		8,097		689,603				697,700
Common stock sold for cash on August 3, 2010				593,211		593		58,728				59,321
Common stock sold for cash on October 1, 2010				661,000		661		78,659				79,320
Common stock sold for cash on November 1, 2010				1,400,000		1,400		142,600				144,000
Common stock sold for cash on November 22, 2010				350,000		350		41,650				42,000
Common stock sold for cash on January 10, 2011				110,000		110		11,990				12,100
Common stock sold for cash on February 14, 2011				1,920,000		1,920		190,080				192,000
Common stock sold for cash on March 2, 2011				290,000		290		28,710				29,000
Common stock sold for cash on March 10, 2011				176,923		177		14,823				15,000
Common stock issued as payment of short-term loan into stock on February 14, 2011				1,000,000		1,000		99,000				100,000
Warrants issued as payment for services on November 22, 2010								46,735				46,735
Common stock issued for conversion of note payable on February 8, 2011				30,769		31		1,967				1,998
Common stock issued for conversion of note payable on February 11, 2011				15,385		15		985				1,000
Common stock issued for conversion of note payable on February 16, 2011				26,154		26		1,674				1,700
Common stock issued for conversion of note payable on February 17, 2011				15,385		15		985				1,000
Common stock issued for conversion of note payable on February 22, 2011				21,927		22		1,475				1,497
Common stock issued for conversion of note payable on February 28, 2011				55,749		56		3,568				3,624
Common stock issued for conversion of note payable on March 7, 2011				24,796		25		1,506				1,531
Common stock issued for conversion of note payable on March 8, 2011				18,100		18		982				1,000
Common stock issued for conversion of note payable on March 14, 2011				109,783		110		5,956				6,066
Common stock issued for conversion of note payable on March 28, 2011				51,282		51		2,949				3,000
Common stock issued for conversion of note payable on March 30, 2011				59,829		60		3,440				3,500
Common stock issued for conversion of note payable on April 4, 2011				59,829		60		3,440				3,500
Common stock issued for conversion of note payable on April 5, 2011				24,376		24		1,402				1,426
Amortization of restricted stock issued for services								786,275				786,275
Dividends on preferred stock										(6,000)		(6,000)
Net loss										(3,295,428)		(3,295,428)

Balance at June 30, 2011	111,111	$	111	153,799,715	$	153,800	$	15,954,280	$	(16,848,488)	$	(740,297)

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) (Continued)

										Deficit
										Accumulated
										During the
	Series A Preferred			Common Stock				Additional Paid-in		Development
	Shares		Amount	Shares		Amount		Capital		Stage		Total

Balance at June 30, 2011	111,111	$	111	153,799,715	$	153,800	$	15,954,280	$	(16,848,488)	$	(740,297)

Common stock issued as payment for services on July 13, 2011				379,449		380		25,968				26,348
Common stock issued as payment for services on August 19, 2011				198,879		199		10,541				10,740
Common stock issued as payment for services on August 22, 2011				230,000		230		12,191				12,421
Common stock issued as payment for services on September 29, 2011				366,924		367		13,787				14,154
Common stock issued for conversion of note payable on August 16, 2011				287,356		287		20,786				21,073
Common stock issued for conversion of note payable on August 17, 2011				391,850		392		25,949				26,341
Common stock issued for conversion of note payable on August 19, 2011				391,850		392		25,949				26,341
Common stock issued for conversion of note payable on August 22, 2011				288,401		288		17,216				17,504
Common stock issued for conversion of note payable on September 13, 2011				30,769		31		1,508				1,539
Common stock issued for conversion of note payable on September 15, 2011				46,154		46		2,262				2,308
Common stock issued for conversion of note payable on September 16 2011				76,923		77		4,538				4,615
Common stock sold for cash on August 22, 2011				600,000		600		34,400				35,000
Common stock issued for conversion of note payable on October 4, 2011				130,474		130		4,818				4,948
Common stock issued for conversion of note payable on October 5, 2011				178,891		179		6,943				7,122
Common stock issued for conversion of note payable on October 6, 2011				429,338		429		16,663				17,092
Common stock issued for conversion of note payable on October 10, 2011				35,778		36		1,388				1,424
Common stock issued for conversion of note payable on October 11, 2011				194,231		194		6,929				7,123
Common stock issued as payment for services on October 25, 2011				44,000		44		1,653				1,697
Common stock issued as payment for services on November 1, 2011				353,959		354		13,300				13,654
Common stock issued as payment for services on November 22, 2011				87,500		88		2,612				2,700
To record prepayment of convertible promissory note December 6, 2011								24,591				24,591
Common stock issued for conversion of note payable on January 25, 2012				230,769		231		6,692				6,923
Common stock issued for conversion of note payable on January 26, 2012				179,487		179		5,205				5,384
Common stock issued for conversion of note payable on January 27, 2012				102,564		103		4,000				4,103
Common stock issued for conversion of note payable on January 30, 2012				76,923		77		3,000				3,077
Common stock issued for conversion of note payable on January 31, 2012				338,462		338		13,200				13,538
Common stock issued for conversion of note payable on February 1, 2012				153,846		154		6,000				6,154
Common stock issued for conversion of note payable on February 17, 2012				50,441		50		2,063				2,113
Common stock issued for conversion of note payable on February 21, 2012				249,750		250		9,740				9,990
Common stock issued for conversion of note payable on March 5, 2012				82,124		82		2,382				2,464
Common stock issued for conversion of note payable on March 9, 2012				122,587		123		3,555				3,678
Common stock issued for conversion of note payable on March 12, 2012				183,880		184		5,333				5,517
Common stock issued for conversion of note payable on March 13, 2012				91,940		92		2,666				2,758
Common stock issued for conversion of note payable on March 16, 2012				61,538		62		1,785				1,847
Common stock issued for conversion of note payable on March 26, 2012				200,669		201		5,819				6,020
Common stock issued for conversion of note payable on March 27, 2012				66,890		67		1,940				2,007
Common stock issued for conversion of note payable on March 29, 2012				100,334		100		2,910				3,010
Common stock issued for conversion of note payable on March 30, 2012				196,399		196		5,696				5,892
Issuance of stock options as payment for services on February 16, 2012								168,928				168,928
Common stock issued as payment for services on January 5, 2012				140,792		141		5,290				5,431
Common stock issued as payment for services on February 7, 2012				87,500		88		1,937				2,025
Common stock issued as payment for services on February 16, 2012				2,000,000		2,000		44,290				46,290
Conversion of Convertible Preferred Shares to Common Shares on March 18, 2012	(111,111)		(111)	442,570		443		17,687				18,019
Common stock issued for conversion of note payable on April 3, 2012				60,096		60		1,743				1,803
Common stock issued for conversion of note payable on April 17, 2012				60,332		60		1,750				1,810
Common stock issued for conversion of note payable on April 19, 2012				66,365		66		1,925				1,991
Common stock issued for conversion of note payable on April 23, 2012				267,559		268		7,758				8,026
Common stock issued for conversion of note payable on April 23, 2012				113,311		113		3,286				3,399
Common stock issued for conversion of note payable on June 1, 2012				-		-		5,136				5,136
Issuance of stock options as payment for services on March 31, 2012				-		-		16,570				16,570
Issuance of stock options as payment for services on March 31, 2012				-		-		570				570
Issuance of stock options as payment for services on June 30, 2012				-		-		34,271				34,271
Issuance of stock options as payment for services on June 30, 2012				-		-		1,172				1,172
Common stock issued as payment for services on June 3, 2012				200,000		200		4,429				4,629
Common stock issued for conversion of note payable on June 6, 2012				1,500,000		1,500		23,960				25,460
Dividends on Preferred Stock										(4,286)		(4,286)
Net loss										(1,928,128)		(1,928,128)
Balance at June 30, 2012	-	$	-	165,969,569	$	165,971	$	16,650,959	$	(18,780,902)	$	(1,963,972)
Issuance of stock options as payment for services on June 30, 2012				-		-		1,185				1,185
Issuance of stock options as payment for services on Sept 30, 2012				-		-		34,647				34,647
Common stock returned in exchange for payment of convertible debt				(1,500,000)		(1,500)		(23,960)				(25,460)
Common stock and options returned in exchange for warrants October 12, 2012				(2,000,000)		(2,000)		(39,427)				(41,427)
Common stock issued as payment for services December 18, 2012				1,000,000		1,000		29,000				30,000
Issuance of warrants with convertible debt December 17, 2012								95,002				95,002
Common stock returned in exchange for options December 18, 2012				(6,800,858)		(6,801)		6,801				-
Restricted common stock issued as payment for services December 18, 2012				231,000		231		6,699				6,930
Issuance of stock options as payment for services on December 31, 2012								74,189				74,189
Adjustment for common stock returned in 2011				(9)								-
Issuance of stock options as payment for services on March 31, 2013								1,185				1,185
Net Loss										(39,871)		(39,871)
Balance at March 31, 2013	-	$	-	156,899,702	$	156,901	$	16,836,280	$	(18,820,773)	$	(1,827,592)

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS

						January 29, 2007,
						Inception,
		For the Nine Months Ended				Through
		March 31,				March 31,
		2013		2012		2013

Operating activities:
Net loss	$	(39,871)	$	(1,355,267)	$	(18,637,662)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization		47,106		37,730		148,356
Warrants issued in connection with convertible notes payable		-		-		49,245
Amortization of convertible loan discount		38,258		95,345		468,707
Use of advances against revenue		(284,337)		-		(284,337)
Common stock issued for services		36,930		135,459		11,702,990
Stock option compensation		69,779		168,928		598,802
Warrants issued for services		-		-		337,359
Change in value of derivatives		(25,430)		(18,489)		(25,240)
Equipment write-down		-		-		5,399
Patent write-down		-		21,758		35,258
Effect of changes in:						-
Inventory		(13,152)		(32,982)		(114,789)
Prepaid expenses and other current assets		-		(5,516)		(20,516)
Advances to related parties		7,353		(21,120)		67,145
Deposits		-		-		(9,500)
Accounts payable and accrued expenses		(125,989)		150,811		200,645
Accrued payroll		269,169		484,201		1,521,625
Deferred revenue		(247,444)		130,493		36,534
Net cash used in operating activities		(267,628)		(208,649)		(3,919,979)

Investing activities:
Purchase of property and equipment		(51,186)		(17,719)		(172,930)
Payments for systems		-		-		(152,721)
Payments for patents		(28,153)		(23,750)		(193,787)
Advance to Related Party		(30,000)		-		(30,000)
Net cash used in investing activities		(109,339)		(41,469)		(549,438)

Financing activities:
Proceeds from (payments on) bank loan borrowings		(349,276)		(115,839)		(0)
Proceeds from sales of preferred stock		-		-		725,000
Proceeds from convertible notes payable		153,000		132,500		624,212
Payments on convertible notes payable		(108,000)		(47,500)		(163,000)
Proceeds from sales of common stock		-		35,000		2,139,690
Payments on related party short-term loans		-		(15,750)		-
Proceeds from related party short-term loans		(100,000)		-		-
Proceeds from short-term loans		-		157,000		398,521
Advances againat sales		1,000,000		100,000		1,125,000
Payments of short term loans		(55,000)		(5,000)		(79,000)
Net cash provided by financing activities		540,724		240,411		4,770,423
Net increase in cash		163,757		(9,707)		301,006
Cash, beginning of period		137,249		14,779		-
Cash, end of period	$	301,006	$	5,072	$	301,006

Supplemental disclosures of cash flow information:
Cash paid for interest	$	44,359	$	23,494	$	307,231
Cash paid for income taxes	$	-	$	1,600	$	8,328
Supplemental disclosure of non-cash investing and financing activities:
Warrants issued in connection with preferred stock	$	-	$	-	$	155,714
Beneficial conversion feature on preferred stock	$	-	$	-	$	11,111
Conversion of preferred to common shares in reverse merger	$	-	$	-	$	625,000
Proceeds from sales of preferred shares used to purchase shares of Bio	$	-	$	-	$	400,000
Conversion of note payable to common stock	$	-	$	-	$	278,922
Conversion of short-term loan to common stock	$	-	$	-	$	100,000
Accrued dividends issued to preferred stockholders	$	-	$	4,286	$	13,733
Conversion of convertible notes payable and accrued interest to common stock	$	25,460	$	120,593	$	399,233

See accompanying notes, which are an integral part of these financial statements

CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
March 31, 2013

Note 1 - Nature of Operations and Basis of Presentation

Hydrodynamic Technology, Inc. was incorporated January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as the "Company," "CTi," "we," "us," and "our"), a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi is a California-based development stage company that has developed, patented, and commercialized proprietary technology for processing soybean oil through a device called the Nano ® (the "Reactor"). The Reactor is the critical component of the Nano Neutralization® System which is designed to reduce operating costs and increase yields in the refining of vegetable oils.

Basis of Presentation

We have prepared the accompanying consolidated unaudited financial statements of the Company in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the nine months ended March 31, 2013 are not indicative of the results that may be expected for the fiscal year ending June 30, 2013. You should read these unaudited consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2012.

Note 2 - Going Concern

Management's Plan Regarding Going Concern

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern. The Company has no significant operating history and, from January 29, 2007, (inception), through March 31, 2013, generated a net loss of $18,820,773. Since inception, we recorded revenue of $2,000,257; with revenue in the third quarter of fiscal 2013 being $529,327. The Company also has negative cash flow from operations and negative net equity. Cumulative net cash of $3,919,979 used in operating activities, and of $549,438 used in investing activities was funded largely with $2.9 million in equity and $0.6 million in convertible notes, as well as short term loans in the amount of $0.4 million and advances from a strategic partner of over $1 Million. These factors, among others, raise doubt about the Company's ability to continue as a going concern.

Management's plan is to generate income from operations by licensing our technology globally through our strategic partner, the Desmet Ballestra Group. Through May 2015, Desmet has agreed to provide us limited monthly advances against future sales. As of March 31, 2013, advances received amounted to $1,125,000 of which $284,337 have been applied to current period sales and recognized as revenue. Minimum monthly advances from Desmet amount to $125,000 and should continue monthly for the duration of the agreement. In addition, in the first quarter of fiscal 2013, the Company signed an agreement with the GEA Westfalia Separator Group. The purpose of the agreement is to jointly develop and patent new process applications using CTi's technology.

We will also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

As a result of the aforementioned factors, our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2012 expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.

Note 3 - Summary of Significant Accounting Policies
Patents

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with Accounting Standards Codification ("ASC") 350-30, General Intangibles Other Than Goodwill. As of March 31, 2013, the Company had incurred $147,547 in net patent costs comprised of $157,487 of gross capitalized patents and $9,940 in cumulative amortization. This compares with a net of $123,158 at June 30, 2012 comprised of $129,334 in gross capitalized costs and $6,176 in cumulative amortization. The Company has designed, developed, and patented two proprietary Nano Reactors (Nano Reactor®) and has five US and eleven PCT/international applications pending in processes such as vegetable oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

At March 31, 2013, future amortization of patent costs is estimated as follows:

Year Ended June 30,		Amount
2013	$	5,289
2014		14,771
2015		22,988
2016		25,536
2017		21,711
Thereafter		57,252
Total	$	147,547

Advertising and Promotion Costs

Advertising costs incurred in the normal course of operations are expensed as incurred. Advertising (and marketing) expenses amounted to $23,883, $33,339, and $294,435 for the nine months ended March 31, 2013 and 2012, and the period from January 29, 2007 (date of inception) through March 31, 2013, respectively.

Related Party Advances

The outstanding balance of $46,525 at March 31, 2013 corresponds to an advance of $16,500 to our CEO (who presently is the Company's Chief Technology Officer), and of $30,000 to the Company's President, plus accrued interest.

Deferred Revenue and Advances from Customer

During second quarter of fiscal 2013, we received deposits of $46,651 and $26,753 from Desmet Ballestra for new orders to be shipped to clients in the 3-rd quarter of fiscal 2013. Since the systems were shipped during current quarter, we recognized revenue for these amounts in current quarter. The balance of $36,533 in Advances from Customer account represents part of the advanced payments provided by our marketing partner Desmet Ballestra in prior periods. These amounts will remain in Deferred Revenue on the accompanying consolidated balance sheet until the systems are assembled and shipped.

Advances from Desmet

As of March 31, 2013, total advances received amounted to $1,125,000 of which $325,000 was received in current fiscal quarter. $284,337 of these advances have been applied to current period sales and recognized as revenue. The remaining balance of $840,663 will be applied to future sales.

Fair Value Measurement

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2013 and 2012, the carrying value of certain accounts such as inventory, accounts payable, accrued expenses, accrued payroll and short-term loans approximate fair value due to the short-term nature of such instruments.

The following table presents information about the Company's assets and liabilities measured and reported in the financial statements at fair value on a recurring basis as of March 31, 2013 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. The three levels of the fair value hierarchy are as follows:

Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value

Fair Value Measurements at March 31, 2013

as of

Using Fair Value Heirarchy

Financial Instruments

March 31, 2013

Level 1

Level 2

Level 3

Liabilities:

Derivative liability

Total

The following tables provide a reconciliation of the beginning and ending balances of our financial liabilities classified as Level 3:

Fair Value Measurements Using Significant
Unobservable Inputs (Level 3)
		Derivative Liability

Balance at June 30, 2012	$	6,271
Total (gains) losses included in interest expense and other		(10,281)
Creation - convertible note issuances		15,149
Settlements - note conversions		(11,139)
Balance at March 31, 2013	$	-

Note 4 - Net Loss per Share - Basic and Diluted

The Company computes the loss per common share using ASC 260, Earnings per Share. The net loss per common share, both basic and diluted, is computed based on the weighted average number of shares outstanding for the period. The diluted loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average shares outstanding assuming all potential dilutive common shares were issued.

On March 31, 2013, the Company had 12,861,815 stock options and 14,863,267 warrants outstanding to purchase common stock that were not included in the diluted net loss per common share because the earnings per share were less than $0.01. The Company also had $100,000 of convertible notes payable, before discounts, which are convertible into 3,333,333 shares of common stock as of March 31, 2013. These items were also not included in the calculation of diluted net loss per common share because their effect would be anti-dilutive.

Note 5 - Property and Equipment

Property and equipment consisted of the following as of March 31, 2013 and June 30, 2012.

		December 31,		June 30,
		2012		2012

Leasehold improvement	$	2,475	$	2,475
Furniture		26,837		26,837
Office equipment		1,500		1,499
Equipment		68,380		68,380
Systems		186,208		135,027

		285,400		234,218

Less: accumulated depreciation and amortization		(141,945)		(98,603)

Property and equipment, net	$	143,455	$	135,615

Depreciation and amortization expense amounted to $43,342, $34,711 and $137,378 for the nine months ended March 31, 2013 and 2012, and the period from January 29, 2007 (date of inception) through March 31, 2013, respectively.

Note 6 - Bank Loan

On November 1, 2011, the maturity of the variable rate loan with the National Bank of California was extended to February 1, 2013. Monthly payments included 14 principal payments of $6,000 plus interest. In addition, CTi were to make a quarterly principal payment of $50,000. The Company provided the National Bank of California a security interest in the assets of the Company as collateral for the loan. In addition, the personal assets of our two founders were pledged as collateral. During the quarter ended December 31, 2012, the outstanding balance on the loan, including interest, was fully paid off by the Company.

Note 7 - Short-Term Loans and Short Term Loans - related parties
Short Term Loans

On October 26, 2010, the Company entered into a loan agreement with Desmet Ballestra North America, Inc. under which the Company borrowed $75,000. The outstanding balance on September 30, 2012 was $55,000 with accrued interest of $6,875 and was paid off by the Company during the second fiscal quarter of 2013.

As of June 30, 2012, we had received $34,521 from a third party, and we recorded these funds in Short Term Loans which are due on demand and pay an annual interest rate of 12%. Accrued interest amounts to $3,915 at March 31, 2013.

Short Term Loans - related parties

As of June 30, 2012, we had received $185,000 from West Point Partners, LLC, whose managing partner is the Company's Principal Accounting Officer. These funds are due on demand, and pay an annual interest rate of 12%. Accrued interest which is included in Accrued Expenses amounts to $21,150.

On December 28, 2011, the past CEO, Todd Zelek, extended to the company a $100,000 short-term loan due on demand at an annual interest rate of 12%. In October 2012, the terms of the loan were amended so that the balance of accrued interest at Sept 30, 2012 of $9,000 was to be repaid at $3,000 per month starting in October 2012. Interest is to accrue and be paid monthly at 15% per year, and the entire balance is due October 1, 2013. In addition, principal payments are to be made monthly if the company receives cash in excess of $125,000 per month at an amount of 25% of the excess cash. The Company has repaid the outstanding principal and accrued interest balances of this loan in the current fiscal quarter.

Note 8 - Convertible Notes Payable

On July 12, 2012 we entered into a convertible promissory note with Asher Enterprises, Inc. under which we issued a $53,000 convertible promissory note. The note is due April 13, 2013 and bears interest at 8% per annum. The note is convertible into shares of our common stock at a conversion price equal to 60% of the average of the lowest three (3) Trading Prices for the Common Stock during the ten Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. The note was issued in reliance on Section 4(2) of the Securities Act of 1933. The note was not offered via general solicitation to the public. No sales commissions or other remuneration was paid in connection with the issuance of this note. On November 9, 2012 the note was paid in full including a pre-payment premium of $19,600 and accrued interest of $1,394.

On December 17, 2012 we issued a convertible promissory note payable to a private party in the amount of $100,000 with an interest rate of 12% per annum and due May 31, 2014. The note is convertible into shares of our common stock at a conversion price of $0.03 any time during the life of the note. The note was still outstanding as of March 31, 2013. The note was issued in reliance on Section 4(2) of the Securities Act of 1933. The note was not offered via general solicitation to the public. No sales commissions or other remuneration was paid in connection with the issuance of this note. Also, 3,333,333 warrants were issued in connection with this note, and as a result a discount was recorded against this note. The balance of the discount at March 31, 2013 is $76,370.

Note 9 - Stockholders' Equity

Preferred Stock

The Company has 5,000,000 shares of Series A Preferred Stock authorized with no shares outstanding. The Company has authorized 5,000,000 shares of Preferred Stock as Series B Preferred Stock. The Board of Directors can establish the rights, preferences and privileges of the Series B Preferred Stock. There are no shares of Series B Preferred Stock outstanding

Stock Options

A summary of the stock option activity for the nine months ended March 31, 2013 is presented below.

			Weighted-
			Average
		Weighted-	Remaining
		Average	Contractual
		Exercise	Life
	Options	Price	(Years)


Outstanding June 30, 2012	13,560,957	$ 0.10	8.95

- Granted	9,300,858	0.03	10.00
- Forfeited	(10,000,000)	0.03	4.00
- Exercised	-	-	-
- Expired	-	-	-

Outstanding March 31, 2013	12,861,815	$ 0.10	8.31

Vested and expected to vest at March 31, 2013	11,736,815

Exercisable at March 31, 2013	11,736,815	$ 0.10	8.13

The following table summarizes information about outstanding stock options as of March 31, 2013.

		Options Outstanding				Options Exercisable
			Weighted		Weighted		Weighted
			Average		Average		Average
	Exercise	Number	Remaining		Exercise	Number	Remaining
	Price	of Shares	Life (Years)		Price	of Shares	Life (Years)

$	0.03	11,050,858	9.02	$	0.03	9,925,858	9.36
$	0.33	637,297	3.56	$	0.33	637,297	3.56
$	0.67	1,173,660	3.91	$	0.67	1,173,660	3.91
		12,861,815				11,736,815

Warrants

A summary of the warrant activity for the nine months ended March 31, 2013 is presented below.

				Weighted-
				Average
			Weighted-	Remaining
			Average	Contractual
			Exercise	Life
	Warrants		Price	(Years)
Outstanding at June 30, 2012	11,222,287	$	0.42	0.62
Granted	10,833,333		0.06	7.44
Exercised	-		-	-
Expired	7,192,353		0.42	-
Outstanding at March 31, 2013	14,853,267	$	0.16	5.65

Vested and expected to vest at March 31, 2013	14,853,267	$	0.16	5.65

Exercisable at March 31, 2013	14,853,267	$	0.16	5.65

The following table summarizes information about outstanding warrants as of March 31, 2013.

		Warrants Outstanding				Warrants Exercisable
			Weighted		Weighted			Weighted
			Average		Average			Average
	Exercise	Number	Remaining		Exercise	Number		Exercise
	Price	of Shares	Life (Years)		Price	of Shares		Price

$	0.05 - 0.07	10,833,333	7.44	$	0.06	10,833,333	$	0.06
$	0.20 - 0.37	1,529,934	0.78	$	0.27	1,529,934	$	0.27
$	0.42 - 0.58	2,500,000	0.89	$	0.52	2,500,000	$	0.52
		14,863,267				14,863,267

Note 10 - Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under ASC 270, Interim Financial Reporting, the Company is required to adjust its effective tax rate each quarter to be consistent with the estimated annual effective tax rate. The Company is also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, jurisdictions with a projected loss for the year or a year-to-date loss where no tax benefit can be recognized are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter based upon the mix and timing of actual earnings versus annual projections. The Company has estimated its annual effective tax rate to be zero. This is based on an expectation that the Company will generate net operating losses in the year ending June 30, 2013, and it is not more likely than not that those losses will be recovered using future taxable income. Therefore, no provision for income tax or tax liability has been recorded as of and for the period ended March 31, 2013.

ASC 740-10, Accounting for Uncertainty in Income Taxes, indicates criteria that an individual tax position must satisfy for some or all of the benefits of that position to be recognized in the financial statements. ASC 740-10 includes a higher standard that tax benefits must meet before they can be recognized in a company's financial statements. As the Company has no uncertain tax positions as defined in ASC 740, there are no corresponding unrecognized tax benefits. Any future changes in the unrecognized tax benefit will have no impact on the Company's effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. It is the Company's policy to classify income tax penalties and interest, if any, as part of general and administrative expense in its Statements of Operations. The Company has not incurred interest or penalties since inception.

Note 11 - Commitments and Contingencies

Lease Agreements

Total rent expense was $40,597, $40,115, and $347,729 for the nine months ended March 31, 2013 and 2012, and for the period from January 29, 2007 (date of inception) through March 31, 2013, respectively. The Company has renewed its lease agreement during current quarter for 3 more years and it is now extends through February 1, 2016 with monthly rental payments of $4,511.

Royalty Agreements

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President as well as our former CEO/current CTO, where certain devices and methods involved in the hydrodynamic cavitation processes invented by these two individuals have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of these two individuals for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company's CTO and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through March 31, 2013.

On April 30, 2008 (as amended November 22, 2010), our wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the "Inventor") who shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of March 31, 2013, no patents have been granted in which this person is the legally named inventor.

Licensing Agreement

On May 14, 2012, we signed a 3-year R and D, Marketing and Technology License Agreement (the "Agreement") with n.v. Desmet Ballestra Group, s.a. ("Desmet"). The Agreement provides Desmet (licensee) an exclusive license and right to develop, design and supply systems which incorporate Nano Reactor® devices on a global basis but limited to oils and fats and oleo chemical applications. CTi (licensor) remains owner of the current patents and patent applications but Desmet will be co-owner of any new process patent applications jointly developed. Desmet has agreed to provide limited monthly advance payments on future sales to CTi, if necessary, in the amount of $125,000. Payments made by Desmet during the nine months ended March 31, 2013 amounted to $1,000,000.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

Overview of our Business

Hydrodynamic Technology, Inc. was incorporated January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") a Nevada corporation originally incorporated under the name Bio Energy, Inc. Cavitation Technologies, Inc. has developed, patented, and commercialized proprietary technology for processing soybean oil through a device called the Nano Reactor (the "Reactor" that employs proprietary continuous flow- through, hydrodynamic NANO Technology in the form of our multi-stage NANO Series of reactors. The Reactor is the critical component of the Nano Neutralization System - a vegetable oil refining system which is designed to reduce operating costs and increase yields.

During the quarter ended March 31, 2013, we recorded $529,327 in revenue. Cumulative loss since inception on January 29, 2007 is $18,820,773 including non-monetary expense of $11,702,990 in common stock issued for services. Cumulative net cash of $3,919,979 used in operating activities, and of $549,438 used in investing activities was funded largely with $2.9 million in equity and $0.6 million in convertible notes, as well as short term loans in the amount of $0.4 million and advances from a strategic partner of over $1 Million.

Management's Plan

We are a development stage entity engaged in merchandising our NANO Neutralization System which is designed to help refine vegetable oils such as soybean, canola, and rapeseed. Our near term goal is to successfully merchandise our systems. We have no significant operating history and, from January 29, 2007, (inception), through December 31, 2012 generated a net loss of $18,615,343. We also have negative cash flow from operations and negative net equity. The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.

Management's plan is to generate income from operations by licensing our technology globally through our strategic partner, the Desmet Ballestra Group. We will also attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

Critical Accounting Policies

CTi's critical accounting policies and estimates are included in its Annual Report on Form 10-K for the year ended June 30, 2012, and did not change for the nine months ended March 31, 2013.

Results of Operations

The following is a comparison of our results of operations for the three months ended March 31, 2013 and 2012.

		For the Three Months Ended
		March 31,
		2013		2012		$ Change	% Change
		(Unaudited)		(Unaudited)

Revenue	$	529,327	$	51,818	$	477,509	921.5%
Cost of sales		16,726		12,260		4,466	36.4%
Gross profit		512,601		39,558		473,043	1195.8%
General and administrative expenses		296,647		502,820		(206,173)	-41.0%
Research and development expenses		18,341		64,735		(46,394)	-71.7%
Total operating expenses		314,988		567,555		(252,567)	-44.5%
Income (loss) from operations		197,613		(527,997)		725,610	-137.4%
Interest expense & other		(26,948)		(25,337)		(1,611)	6.4%
Loss before income taxes		170,665		(553,334)		723,999	-130.8%
Income tax expense		-		-		-	0.0%
Net income (loss)	$	170,665	$	(553,334)	$	723,999	-130.8%

Revenue

During the three months ended March 31, 2013, our revenue consisted of two NANO Neutralization System reactor sales and license fees of $235,735 and $293,567, respectively, to clients in South Dakota and Argentina. This compares with $51,818 recorded during the same period in fiscal 2012 derived from the sale of a Nano Reactor® Device, rental income from a trial unit, and service fees associated with the Nano Reactor® System.

Cost of Revenue

During the three months ended March 31, 2013, our cost of sales amounted to $16,726 which was the result of the reactor sales described above and primarily consists of the cost incurred for manufacturing Nano reactors and engineering work involved to assemble them.

Operating Expenses

Operating expenses for the three months ended March 31, 2013 amounted to $314,988 compared with $567,555 for the same period in 2012, a decrease of $252,567, or 44.5%. The decrease was attributable to a $206K reduction in G&A and $46K drop in R&D expenses.

In the third quarter of fiscal 2013, compensation amounted to $97,094, or 28% of total costs compared with $365,191, or 64% in the second quarter of fiscal 2012. This decrease in compensation in the third quarter of fiscal 2013 was attributable largely to the reduction in management and its salaries, as well as a reduction of non-monetary compensation, such as stock options, in the current fiscal quarter.

The other major components of $296,647 in G&A expenses in the third quarter of fiscal 2013 included $53,529 in consulting fees and $57,449 in professional fees largely for audit and accounting services compared with $17,025 in consulting and $47,157 in professional fees in the same period in fiscal 2012. These expenses were higher in the third quarter of fiscal 2013 as we reduced reliance on salaried management and engaged third-party service providers on a more frequent basis. Other significant expenses for the third quarter of 2013 were Marketing, Insurance (mostly health insurance) and Travel, with Depreciation a leading non-cash expense. These expenses cumulatively amounted to about $56K, or 18% of all operating expenses for the quarter.

R&D expenses remained relatively low at $18,341 as we continued to rely on Desmet Ballestra for support in R&D. It is our intention to pursue R&D as our cash position permits.

Interest Expense

In the third quarter of fiscal 2013, Interest Expense amounted to $26,948, a decrease of $1,600 or 6% compared to $25,337 in the same period of fiscal 2012. It consisted of a non-cash expense of $16,122 relating to convertible notes amortization, $6,586 in non-cash, accrued interest relating primarily to short term loans, and cash interest paid mostly to convertible note holders in the amount of over $4,000. Most of interest expense for the 3 months ended on March 31, 2012 was non-cash charges associated with convertible notes payable. Cash interest payments on our bank line of credit amounted to $7,196 for the third quarter of 2012. Cash interest payments on our loan from the National Bank of California declined to $0 as the outstanding balance was paid down in the prior fiscal quarter and were substituted by payments to convertible note holder.

Results of Operations for the Nine Months Ended March 31, 2013 Compared to the Nine Months Ended March 31, 2012.

The following is a comparison of our results of operations for the nine months ended March 31, 2013 and 2012.

		For the Nine Months Ended
		March 31,
		2013		2012		$ Change	% Change
		(Unaudited)		(Unaudited)

Revenue	$	1,223,115	$	165,972	$	1,057,143	636.9%
Cost of sales		21,665		35,274		(13,609)	-38.6%
Gross profit		1,201,450		130,698		1,070,752	819.3%
General and administrative expenses		1,063,089		1,203,887		(140,798)	-11.7%
Research and development expenses		84,194		126,940		(42,746)	-33.7%
Total operating expenses		1,147,283		1,330,827		(183,544)	-13.8%
Loss from operations		54,167		(1,200,129)		1,254,296	-104.5%
Interest expense		(94,038)		(155,138)		61,100	-39.4%
Loss before income taxes		(39,871)		(1,355,267)		1,315,396	-97.1%
Income tax expense		-		-		-	0.0%
Net loss	$	(39,871)	$	(1,355,267)	$	1,315,396	-97.1%

Revenue

During the nine months ended March 31, 2012, our revenue consisted of NANO Neutralization System reactor sales of $285,735 to clients in Argentina and South Dakota, as well as license fees in the amount of $937,355 due to final acceptance of our systems by clients in Europe and the US in addition to license fees on the current period reactor sales. This compares with $165,972 recorded during the same period in fiscal 2012 associated primarily with the sale of a NANO Neutralization System to customers located in Argentina, Europe and the US.

Cost of Revenue

During the nine months ended March 31, 2013, our cost of sales amounted to $21,665 which was the result of the reactor sales described above.

Operating Expenses

Operating expenses for the nine months ended March 31, 2013 amounted to $1,147,283 compared with $1,330,827 for the same period in 2012, a decrease of $183,544, or 14%. The decrease was attributable to a $140,798 decline in G&A and $42,746 decrease in R&D expenses.

The primary expenditures during the first three quarters of fiscal 2013 were $140K for professional service fees such as auditors, attorneys, and SEC related services, consulting fees of $95K, insurance expense of $75K (mostly health insurance accrual), and depreciation and commission expenses of about $43K each, and $495K in salaries and salary related expenses. The major components of G&A during the nine months ended March 31, 2012 were compensation of $639,781 and professional services such as auditors, attorneys, and SEC related services of $248,488. This decrease in major expenses in the fiscal 2013 was attributable largely to the reduction in management compensation and more effective use of available resources.

Interest Expense

Interest expense decreased by $61,100, or 39%, for the nine months ended March 31, 2013 as compared to 2012. Interest expense for the nine months ended March 31, 2013 consisted of a non-cash expense of $38,247 relating to convertible notes, $27,522 in mostly non-cash, accrued interest relating primarily to short term loans, and cash interest paid to convertible note holders in the amount of about $52K. Cash interest payments on our loan from the National Bank of California declined to $11,020 during fiscal 2013 as the outstanding balance declined from $370,271 at March 31, 2012 to $0 on March 31, 2013.

Interest expense for the 9 months ended March 31, 2012 amounted to $155,138, and mostly consisted of non-cash charges associated with convertible notes payable. Cash interest payments on our bank line of credit amounted to $22,502 the nine months ended March 31, 2012 and we incurred a cash interest expense of $23,750 associated with the pre-payment of a $47,500 convertible promissory note.

Liquidity and Capital Resources

CTi's primary sources of liquidity derived largely from payments for reactors and licensing fees, as well as advances on future sales from Desmet Ballestra, and convertible promissory notes and short-term loans. See Note 7 "Short-Term Loans and Short Term Loans - related parties" and Note 8 "Convertible Notes Payable," for more information.

Common Stock

During the nine months ended March 31, 2013, we did not issue any stock for cash, compared with 600,000 shares of common stock for $35,000 for the nine months ended March 31, 2012. In August of 2012 the 1,500,000 shares issued to Prolific for note conversion were returned to the company and the note was reinstated (and subsequently paid off).

Share-based Compensation

During the nine months ended March 31, 2013 we issued 1,231,000 shares of restricted common stock valued at $36,930 as payment to service providers, of which 231,000 were issued to Director of R&D. Also, 6,800,858 shares of restricted stock previously issued to the Company's CTO, President and a service provider were cancelled and replaced with 6,800,858 options vested immediately. In addition, the company's CTO and President received additional 2,500,000 options each with immediate vesting for services provided during 5 years. We also previously issued 10,000,000 options to our ex-CEO as well as 2,000,000 restricted shares. As part of the separation agreement with CEO on October 12, 2012, the aforementioned options and shares were cancelled and replaced with 7,500,000 warrants.

During the nine months ended March 31, 2012 we issued 3,889,003 shares of restricted common stock valued at $135,459 as payment to service providers including compensation to our CEO. In addition, we amortized restricted stock valued at $786,275 and issued 1,250,000 stock options which vested immediately to our Chief Chemist. During the same period we also issued 10,000,000 shares to our CEO half of which vested immediately and half of which vest in one year.

Cash Flow

Net cash used by operating activities during the nine months ended March 31, 2013 amounted to $267,628 compared with $208,649 cash used up for the same period in fiscal 2012. Funding for the operating and investing activities in the fiscal 2013 was provided by $1,000,000 in advances against sales from Desmet, some of which were recognized as revenue, as well as by $642K received from Desmet for the reactors sold and as licensing fee.

During the nine months ended March 31, 2013, the net cash used in operating activities was used largely to pay salary and related expenses, R&D, interest expense and professional fees such as attorneys, consultants and accountants. Net cash used in investing activities during the nine months ended March 31, 2013 was $109,339, with $28,153 relating to capitalized patents and $51,186 for property, plant, and equipment.

For the first three quarters of fiscal 2013, financing activities were funded by $1M in advances against sales from Desmet along with $153,000 in convertible debt. With this funding, we repaid $55,000 in existing convertible debt, $350K of principal on the bank loan, and $53,000 in repayment of a convertible note payable as well as interest on various notes and $155K in short term loans. Net cash provided by financing activities during the nine months ended March 31, 2013 amounted to $540K. By comparison, for the nine months ended March 31, 2012, cash used in operating activities of $208,649 plus cash used in investing activities of $41,469 were funded largely by financing of $240,411. Major non-operational uses of cash for the nine months ended March 31, 2012 were $115,839 in repayment of principal on the bank loan and $47,500 in repayment of a convertible note payable.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable for smaller reporting companies.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Principal Executive Officer and Principal Accounting officer have evaluated the Company's disclosure controls and procedures as defined in Rules 13a-15(b)(e) and 15d-15(b)(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report, and they have concluded that these controls and procedures are effective.

Changes in Internal Control over Financial Reporting

There were no changes in internal control over financial reporting during the third quarter of fiscal 2013 that have materially affected or are reasonably likely to materially affect the company's internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1 Legal Proceedings

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

The following is a listing of unregistered security activity during the nine months ended March 31, 2013.

Issuance of Common Stock for Conversion of Indebtedness

On June 6, 2012, a conversion request was submitted by the Prolific Group, LLC for $21,450 of outstanding convertible notes corresponding to 1,500,000 shares of common stock. These shares were issued but subsequently returned to the Company in the first quarter of fiscal 2013, and the note of $25,000 was paid in full in two payments of $15,000 on July 12 and $10,000 on August 7 plus a pre-payment premium of $12,593 recorded as interest expense in the Statements of Operations.

Issuance of Restricted Common Stock for Services

On December 18, 2012, we issued 650,000 shares of common stock with a recorded value of $19,500 to Star Funding LLC for professional services. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public but solely to the aforementioned service provider. The Company issued restricted shares in connection with these issuances. No sales commissions or other remuneration was paid in connection with these issuances.

On December 18, 2012, we issued 350,000 shares of common stock with a recorded value of $10,500 to Pinnacle Financial Group for professional services. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public but solely to the aforementioned service provider. The Company issued restricted shares in connection with these issuances. No sales commissions or other remuneration was paid in connection with these issuances.

On December 18, 2012, we issued 231,000 shares of common stock with a recorded value of $6,930 to Varvara Grichko, with 50,000 shares issued for services on the Company's Board of Directors, and 181,000 shares issued for services as a Chief Chemist. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public but solely to the aforementioned service provider. The Company issued restricted shares in connection with these issuances. No sales commissions or other remuneration was paid in connection with these issuances.

Cancellation of Common Stock

On October 12, 2012, we cancelled 2,000,000 shares of common stock with a recorded value of $46,290 previously issued to Todd Zelek, our former CEO for employment services.

On December 18, 2012, we cancelled 3,000,000 shares of common stock with a recorded value of $69,444 previously issued to Roman Gordon for employment services.

On December 18, 2012, we cancelled 3,000,000 shares of common stock with a recorded value of $69,444 previously issued to Igor Gorodnitsky, Company's President, for employment services.

On December 18, 2012, we cancelled 800,858 shares of common stock with a recorded value of $18,536 previously issued to Sergei Chernov for consulting services.

Item 3 - Defaults Upon Senior Securities

None

Item 4 - Mine Safety Disclosures

Not applicable.

Item 5 - Other Information

None

Item 6 - EXHIBITS, FINANCIAL STATEMENT SCHEDULES

			Incorporated by Reference
Exhibit		Filed
Number	Exhibit Description	Herewith	Form	Pd. Ending	Exhibit	Filing Date

3(i)(a)	Articles of Incorporation - original name of Bioenergy, Inc.		SB-2	N/A	3.1	October 19, 2006
3(i)(b)	Articles of Incorporation - Amended and Restated		10-Q	December 31, 2008	3-1	February 17, 2009
3(i)( c )	Articles of Incorporation - Amended and Restated		10-Q	June 30, 2009	3-1	May 14, 2009
3(i)(d)	Articles of Incorporation - Amended; increase in authorized shares		8-K	N/A	N/A	October 29, 2009
3(i)(e)	Articles of Incorporation - Certificate of Amendment; forward split		10-Q	September 30, 2009	3-1	November 16, 2009

10.1	Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.		8-K	June 30, 2009	10.1	May 18, 2010
10.2	Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.		8-K	June 30, 2009	10.2	May 18, 2010
10.3	Assignment of Patent Assignment Agreement between the Company and Roman Gordon		8-K	June 30, 2009	10.3	May 18, 2010
10.4	Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky		8-K	June 30, 2009	10.4	May 18, 2010
10.5	Employment Agreement between the Company and Roman Gordon date March 17, 2008		10K/A	June 30, 2009	10.3	October 20, 2011
10.6	Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008		10K/A	June 30, 2009	10.4	October 20, 2011
10.7	Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008		10-Q	December 31, 2010	10.3	February 11, 2011
10.8	Board of Director Agreement - James Fuller		10-Q	December 31, 2011	10.12	October 20, 2011
10.9	Technology and License Agreement with Desmet Ballestra dated 14 May 2012		10-K	June 30, 2012	10.1	October 15, 2012
10.10	Short Term Loan Agreement - CEO		10-K	June 30, 2012	10.11	October 15, 2012
10.11	Loan Agreement - Desmet Ballestra - Oct. 26, 2010

14.1	Code of Business Conduct and Ethics*		10-K	June 30, 2011	14.1	September 28, 2011
31.1	Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002	X
31.2	Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002	X
32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted	X
	pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted	X
	pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**	XBRL Instance Document	X
101.SCH**	XBRL Taxonomy Extension Schema	X
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase	X
101.DEF**	XBRL Taxonomy Extension Definition Linkbase	X
101.LAB**	XBRL Taxonomy Extension Label Linkbase	X
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase	X

*	In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person
	without charge, upon request, a copy of our "Code of Business Conduct and Ethics". A copy may be requested
	by sending an email to info@cavitationtechnologies.com.

**	Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of the securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURE	TITLE	DATE

/s/ Igor Gorodnitsky	President; Member of Board of Directors	May 15, 2013
Igor Gorodnitsky	(Principal Executive Officer)

/s/ N. Voloshin	Principal Accounting Officer	May 15, 2013
N. Voloshin

/s/ Jim Fuller	Audit Committee Chairman, Independent Financial Expert	May 15, 2013
Jim Fuller